Silo Pharma (NASDAQ: SILO) announced it has regained compliance with the Nasdaq minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2), according to a press release.

The company said it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC that, as of June 17, 2026, the compliance matter is closed. Silo Pharma's common stock continues to trade on the Nasdaq Capital Market.

Chief Executive Officer Eric Weisblum commented on the development, saying the company remains confident about its progress toward a first-in-human clinical trial of its lead drug SPC-15, which targets PTSD, and advancing its AI agents platform QwikAgents.

Silo Pharma is a developmental-stage biopharmaceutical company with a portfolio that includes SPC-15 for post-traumatic stress disorder, SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer's disease.